Research is being conducted on the use of biologics for eosinophilic copd, exploring current applications and future prospects. The treatment is also being considered for other conditions, including asthma and autoimmune diseases. The landscape for biologic therapies, including monoclonal antibodies, appears to be evolving, with various trends and perspectives emerging in the management of these diseases.